A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke.

Stem Cells Transl Med · 2024 · PMC10872695 · PMID 38071749

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

An observed trend of improved functional outcomes in recipients of UCB after 5 days post stroke could be explored in future clinical trials.

also in 200 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.